Dyslipidemia Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com

0
shares
Be First to Share ->
Share on Twitter
Share on Google+
Share on LinkedIn
Pin to Pinterest
Share on StumbleUpon
+
What's This?

Dallas, TX (PRWEB) January 27, 2015

The report provides comprehensive information on the therapeutic development for Dyslipidemia. Dyslipidemia is an abnormal amount of cholesterol or fat in the blood. Dyslipidemia comes under consideration in many situations including diabetes, a common cause of lipidemia. Dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus. Complete report is available at http://www.rnrmarketresearch.com/glaucoma-pipeline-review-h1-2015-market-report.html .

It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. Companies discussed in this Dyslipidemia Pipeline Review H1 2015 report include Amgen Inc., Arisaph Pharmaceuticals, Inc., AstraZeneca PLC, Biocon Limited, Cadila Pharmaceuticals Ltd., Cerenis Therapeutics Holding SA, Chong Kun Dang Pharmaceutical Corp., CymaBay Therapeutics, Inc., Daiichi Sankyo Company, Limited, Debiopharm International S.A., Dezima Pharma BV, Dr. Reddy’s Laboratories Limited, Genfit SA, GlaxoSmithKline plc, Hanmi Pharmaceuticals, Co. Ltd., High Point Pharmaceuticals, LLC, Intas Pharmaceuticals Ltd., Jenrin Discovery, Inc., JW Pharmaceutical Corporation, Kissei Pharmaceutical Co., Ltd., Kotobuki Pharmaceutical Co., Ltd., Kowa Company, Ltd., Kymab Limited, Lipicard Technologies Limited, Merck & Co., Inc., Nippon Chemiphar Co., Ltd., Novartis AG, Pfizer Inc., Pharmena SA, Piramal Enterprises Limited, Reviva Pharmaceuticals Inc., Sanofi, Takeda Pharmaceutical Company Limited, Torrent Pharmaceuticals Limited, Zydus Cadila Healthcare Limited.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269513 . (This is a premium report priced at US$ 2000 for a single user License.)

Table of Contents

List of Tables

Number of Products under Development for Dyslipidemia, H1 2015

Number of Products under Development for Dyslipidemia – Comparative Analysis, H1 2015

Number of Products under Development by Companies, H1 2015

Number of Products under Development by Companies, H1 2015 (Contd..1)

Number of Products under Development by Companies, H1 2015 (Contd..2)

Number of Products under Investigation by Universities/Institutes, H1 2015

Comparative Analysis by Late Stage Development, H1 2015

Comparative Analysis by Clinical Stage Development, H1 2015

Comparative Analysis by Early Stage Development, H1 2015

Products under Development by Companies, H1 2015

Products under Development by Companies, H1 2015 (Contd..1)

Products under Development by Companies, H1 2015 (Contd..2)

Products under Investigation by Universities/Institutes, H1 2015

Dyslipidemia – Pipeline by Amgen Inc., H1 2015

Dyslipidemia – Pipeline by Arisaph Pharmaceuticals, Inc., H1 2015

Dyslipidemia – Pipeline by AstraZeneca PLC, H1 2015

Dyslipidemia – Pipeline by Biocon Limited, H1 2015

Dyslipidemia – Pipeline by Cadila Pharmaceuticals Ltd., H1 2015

Dyslipidemia – Pipeline by Cerenis Therapeutics Holding SA, H1 2015

Dyslipidemia – Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015

Dyslipidemia – Pipeline by CymaBay Therapeutics, Inc., H1 2015

Dyslipidemia – Pipeline by Daiichi Sankyo Company, Limited, H1 2015

Dyslipidemia – Pipeline by Debiopharm International S.A., H1 2015

Dyslipidemia – Pipeline by Dezima Pharma BV , H1 2015

Dyslipidemia – Pipeline by Dr. Reddy’s Laboratories Limited, H1 2015

Dyslipidemia – Pipeline by Genfit SA, H1 2015

Dyslipidemia – Pipeline by GlaxoSmithKline plc, H1 2015

Dyslipidemia – Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015

Dyslipidemia – Pipeline by High Point Pharmaceuticals, LLC, H1 2015

Dyslipidemia – Pipeline by Intas Pharmaceuticals Ltd., H1 2015

Dyslipidemia – Pipeline by Jenrin Discovery, Inc., H1 2015

Dyslipidemia – Pipeline by JW Pharmaceutical Corporation, H1 2015

Dyslipidemia – Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015

Dyslipidemia – Pipeline by Kotobuki Pharmaceutical Co., Ltd., H1 2015

Dyslipidemia – Pipeline by Kowa Company, Ltd., H1 2015

Dyslipidemia – Pipeline by Kymab Limited, H1 2015

Dyslipidemia – Pipeline by Lipicard Technologies Limited, H1 2015

Dyslipidemia – Pipeline by Merck & Co., Inc., H1 2015

Dyslipidemia – Pipeline by Nippon Chemiphar Co., Ltd., H1 2015

Dyslipidemia – Pipeline by Novartis AG, H1 2015

Dyslipidemia – Pipeline by Pfizer Inc., H1 2015

Explore more reports on Ophthalmology therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/ophthalmology-therapeutics .

About Us:

RnRMarketResearch.com is an online database of market research reports offering in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.







Leave a Comment

Your email address will not be published. Required fields are marked *